Market closedNon-fractional
Mirum Pharmaceuticals/MIRM
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Mirum Pharmaceuticals
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Ticker
MIRM
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Foster City, United States
Employees
278
Website
www.mirumpharma.com
MIRM Metrics
BasicAdvanced
$1.6B
Market cap
-
P/E ratio
-$3.67
EPS
1.13
Beta
-
Dividend rate
Price and volume
Market cap
$1.6B
Beta
1.13
Financial strength
Current ratio
3.677
Quick ratio
3.379
Long term debt to equity
130.929
Total debt to equity
131.081
Interest coverage (TTM)
-7.51%
Management effectiveness
Return on assets (TTM)
-13.76%
Return on equity (TTM)
-84.40%
Valuation
Price to revenue (TTM)
6.5
Price to book
6.78
Price to tangible book (TTM)
-69.59
Price to free cash flow (TTM)
-34.61
Growth
Revenue change (TTM)
133.90%
Earnings per share change (TTM)
0.05%
3-year earnings per share growth
-9.65%
What the Analysts think about MIRM
Analyst Ratings
Majority rating from 11 analysts.
MIRM Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$69M
-0.43%
Net income
-$25M
-29.21%
Profit margin
-36.41%
-28.91%
MIRM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.94
-$0.57
-$0.66
-$0.54
-
Expected
-$0.80
-$0.63
-$0.24
-$0.48
-$0.49
Surprise
143.90%
-9.30%
171.60%
12.73%
-
MIRM News
AllArticlesVideos
3 Biotech Stocks For The Second Half Of 2024
Seeking Alpha·1 week ago
Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies
Benzinga·3 weeks ago
Mirum's Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mirum Pharmaceuticals stock?
Mirum Pharmaceuticals (MIRM) has a market cap of $1.6B as of July 05, 2024.
What is the P/E ratio for Mirum Pharmaceuticals stock?
The price to earnings (P/E) ratio for Mirum Pharmaceuticals (MIRM) stock is 0 as of July 05, 2024.
Does Mirum Pharmaceuticals stock pay dividends?
No, Mirum Pharmaceuticals (MIRM) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Mirum Pharmaceuticals dividend payment date?
Mirum Pharmaceuticals (MIRM) stock does not pay dividends to its shareholders.
What is the beta indicator for Mirum Pharmaceuticals?
Mirum Pharmaceuticals (MIRM) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Mirum Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.